Bounyasong 2001.

Methods	Randomized controlled trial Generation of allocation sequence: no method reported Allocation concealment: no method reported Blinding: none Inclusion of all randomized participants: 95% (for treatment failure)
Participants	Number: 60 randomized, 57 analysed Inclusion criteria: pregnant women infected with P. falciparum; gestational age at least 28 weeks; not more than 4% parasitized red blood cells; could be followed up at Srisangwal Hospital; could take and tolerate oral form of the medicine and be admitted to the hospital for at least 7 days Exclusion criteria: former medication with quinine, artesunate (including its derivatives), or mefloquine within 28 days; history of quinine, artesunate, or mefloquine allergy; malaria with complications such as shock, renal failure, pulmonary oedema, or cerebral malaria; mixed malarial infection Age in years (mean): artesunate plus mefloquine group 27.207; quinine group 26.143 Parity (mean): artesunate plus mefloquine group 1.59; quinine group 1.36 Early/late pregnancy: second trimester Symptomatic/asymptomatic malaria: number not reported Anaemia on admission: number not reported
Interventions	1. Artesunate plus mefloquine Artesunate: 2 mg/kg loading dose and 1 mg/kg every 12 hours for at least 5 days (until parasites are absent and there is clinical improvement) Mefloquine: 15 mg/kg on day 6 and 10 mg/kg 6 hours later 2. Quinine sulfate: 10 mg/kg every 8 hours for at least 7 days (until clinically recovered)
Outcomes	1. Treatment failure at day 28 2. Fever clearance time 3. Parasite clearance time 4. Haematocrit 5. Birthweight 6. Gestational age at birth 7. Congenital abnormalities 8. Infant development 9. Adverse events Not included in review: 10. Treatment time of parasite presentation 11. Intra‐uterine growth retardation
Notes	Location: Mae Hong Son, Thailand Local malaria endemicity/transmission: not reported Local antimalarial drug resistance: multiple‐drug resistance Supervision of treatment: not reported